Ethical Considerations in Nutrition: Are We What We Eat?
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer...Read More
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimizing the cardiac status of patients with cancer before, during and after their treatment, we are collectively improving the overall outcomes including survival and quality of life. We aim to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.
Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts...
Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Sarah C. Hull, MD, MBE is a board-certified cardiologist and echocardiographer whose clinical practice is focused on...
Sarah C. Hull, MD, MBE is a board-certified cardiologist and echocardiographer whose clinical practice is focused on echocardiography and cardio-oncology (cardiac care of cancer patients) at Yale University. She is the cardiology course director at Yale School of Medicine (YSM) where she also teaches medical ethics to students and cardiology fellows. Additionally, she has served as an ethics consultant to the advanced heart failure and cardiac transplant team at Yale New Haven Hospital (YNHH). She was appointed Associate Director of the Program for Biomedical Ethics at YSM in 2019, and she also serves on the ethics committee at YNHH. Her recent scholarly work has focused on ethical issues involving ventricular assist devices as destination therapy, ethical considerations in the care of patients with recurrent injection drug use related endocarditis, shared decision making in cardio-oncology, nutrition ethics, and ethical issues raised during the COVID pandemic.